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Abstract
Background: Langerhans cell (LC) sarcoma (LCS) is a high-grade neoplasm with overtly malignant cytologic
features and an LC phenotype. We very recently suggested that LC behaves as a reservoir for common dermotropic
Merkel cell polyomavirus (MCPyV) and determined the relationship between LC histiocytosis (LCH), which has an
underlining oncogenic capacity, and MCPyV as a trigger for a reactive process rather than a neoplastic process.
We propose LC to be a reservoir for MCPyV and hypothesize that some LCS subtypes may be related to the MCPyV
agent.
Findings: We examined seven LCS tissues using multiplex quantitative PCR (Q-PCR) and immunohistochemistry
with anti MCPyV large-T (LT) antigen antibody. High viral loads of MCPyV DNA sequences (viral load = relative levels
of MCPyV) were detected (0.328–0.772 copies/cell (Merkel cell carcinoma (MCC) = 1.0)) using Q-PCR in 43% (3/7)
tissues, but LT antigen expression was not observed (0/7).
Conclusions: Frequent MCPyV-DNA amplification suggests that LCS in some patients may be related to MCPyV
infection. Moreover, the higher viral load of LCS (median, 0.453 copies/cell) than low load of LCH (0.003, median of
12 cases) (P < 0.01) may suggest a virally induced tumorigenic process in some LCS. Although the absence of LT
antigen expression may indicate a different role for MCPyV in this pathology, some subtypes of LCS may develop in
the background of MCPyV-infected LC. To the best of our knowledge, this is the first report on the relationship
between MCPyV and LCS. The recent discovery of MCPyV opened new therapeutic avenues for MCC. These data
open novel possibilities for therapeutic interventions against LCS.
Keywords: Merkel cell polyomavirus, Langerhans cell sarcoma, Langerhans cell, Multiplex quantitative PCR
Findings
Background
Merkel cell polyomavirus (MCPyV) was discovered in
2008 and was linked to the pathogenesis of Merkel cell
carcinoma (MCC), which is a rare and aggressive skin
cancer occurring in the dermis of individuals aged
60 years or older [1,2]. Approximately 80% MCC har-
bors MCPyV, indicating its prominent role in the devel-
opment of the disease. Mechanistically, MCPyV-induced
oncogenesis is considered to be induced by MCPyV
large T (LT) antigen through molecular binding with the
retinoblastoma protein [1]. Several tumorigenic pro-
cesses leading to MCC were proposed. One was that the
induced mutations of MCPyV due to long exposure to
ultraviolet light leads to integration of the cytoplasmic
viral sequences into the DNA of originating MCC cells.
MCPyV primarily resides on the skin, and we have de-
tected MCPyV-DNA in the organs of autopsy cases, with
the highest prevalence (53%) in the skin [3].
Because Langerhans cells (LCs) exist above the middle
of the spinous zone of epidermis [4] and can capture ex-
ternal pathogens [5] and because of their ability to play
roles as antigen-presenting cells [6,7], we proposed that
external pathogens may be initially recognized by LC
and may subsequently infect Merkel cells which are
mostly located at the basal cell layer of the epidermis.
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Therefore, we hypothesized that LC were a reservoir for
MCPyV and demonstrated this phenomenon by showing
MCPyV-DNA in microdissected LC of dermatopathic
lymphadenopathy (DLA) [8].
In this study, we hypothesized that LC sarcoma (LCS)
may originate from a long standing reservoir cell for
MCPyV and showed some prevalence of MCPyV-DNA
in LCS with high viral load compared with that in non-
affected LC.
Results
Quantitative PCR (Q-PCR) for MCPyV-DNA in LCS tissues
The results of Q-PCR tissue analysis for MCPyV are
shown in Table 1 with a positive (MCC = 1.0) and nega-
tive control (water = −). MCPyV-DNA sequences in
three of seven tissues from LCS patients were detected
corresponding to high viral loads (0.328–0.772).
Immunohistochemistry for MCPyV-LT antigen
Neither cytoplasmic nor nuclear immuno-reactivity for
this protein was observed in LCS cells as reported in
Figure 1 and Table 1. MCC as a positive control is
shown in Figure 1.
Discussion
LC is an epidermal dendritic cell (DC) with antigen-
presenting cell capacities. Immature DC typically re-
sponds to pathogen exposure by specific maturation
processes that facilitate induction of further innate and
adaptive immune responses [6,9]. However, some vi-
ruses, such as HIV, vaccinia, measles, and dengue, inter-
fere with DC function and maturation to escape the
immune surveillance [9-13].
Buffy coats of healthy donors above 20 years of age ex-
amined for MCPyV-DNA showed a 22% prevalence [14].
In this study [14] the cellular reservoir was not shown.
In another investigation [15], CD14+ activated mono-
cytes in peripheral blood were shown to serve as a reser-
voir for MCPyV. Recently we have described the
prevalence of MCPyV in human tissues from 41 autopsy
cases, i.e., skin (53%), lymph node (0%, excluding DLA),
and lung (8%), with low viral load (viral load = 0.00026–
0.22) [3]. Our data indicated the possibility that MCPyV
is a dermotropic virus. We have previously shown the
prevalence of MCPyV in LC in DLA tissues (viral load =
0.001–0.006) and in LC histiocytosis (LCH) lesions (viral
load = 0.0001–0.033) [8]. Our data using DLA tissue, in
which epidermal LCs with MCPyV migrate into lymph
nodes [16,17], suggest that LC is a candidate reservoir of
MCPyV in the epidermis. MCPyV may also interfere
with LC functions similar to some viruses, as mentioned
above.
In this study, we have shown the presence of MCPyV
in LCS with high viral loads (Table 1, viral load = 0.328–
0.772). MCPyV-positive LCS samples were compared
with MCPyV-positive LCH samples [8] in the point of
MCPyV viral load in Figure 2 with significant difference
(P < 0.01). The presence of MCPyV in LCS lesions sug-
gests three possibilities: a) viral infection as a conse-
quence of LCS development, b) LCS as a bystander, and
c) a viral causal agent of LCS. Though MCPyV is typic-
ally an asymptomatic infection in adults [18], the pres-
ence of MCPyV with high viral loads denies the
possibility it is a simple bystander within LCS lesions.
Whether MCPyV-DNA is integrated into the nuclei of
LCS cells as an oncogenic virus warrants further investi-
gations, but the high viral loads of MCPyV in LCS lesions
may suggest an important oncogenic factor in LCS cells.
We are now trying specific PCR as Sastre-Garau et al.
Table 1 Clinical characteristics and lesional MCPyV data








LCS1 81 F Skin - -
LCS2 73 M LN - -
LCS3 72 F Salivary
gland
+ (0.453) -
LCS4 61 M Lung + (0.772) -
LCS5 62 M LN + (0.328) -
LCS6 40 M LN - -
LCS7 81 F LN - -
The median age of the LCS patients (n = 7) was 72 years (range, 42–81 years
of age). *Positive control (MCC):+ (Viral load = 1.0), Negative control (double
distilled water): −. Viral load, relative levels of MCPyV. Abbreviations: LCS
Langerhans cell sarcoma, LN lymph node, MCC Merkel cell carcinoma, MCPyV
Merkel cell polyomavirus, Q-PCR multiplex quantitative PCR for MCPyV.
Figure 1 No immunoreactivity for MCPyV-LT using CM2B4
antibody in LCS tissue lesion (LCS4). Insert: MCC tissue lesion as a
positive control. Scale bar, 50 μm. Abbreviations: CM2B4, a
monoclonal antibody to MCPyV-LT; LCS, Langerhans cell sarcoma;
MCC, Merkel cell carcinoma; MCPyV, Merkel cell polyomavirus;
MCPyV-LT, large T antigen protein of MCPyV.
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did [19]. Immunohistochemical negativity for MCPyV-
LT (CM2B4) may indicate a different tumorigenetic
mechanism that is involved in MCPyV-LT positive MCC
[1,20] or under the limit of detection for MCPyV-LT.
Conclusion
To the best of our knowledge, this is the first report in-
dicating a relationship between MCPyV infection and
LCS. Thus, we suggest that MCPyV may play some role
as an oncogenic factor in particular subtypes of LCS.
Based on the foregoing, we propose an LCS tumorigen-
esis model that MCPyV may be a cause of LCS. The re-
cent discovery of MCPyV opened new therapeutic
avenues for MCC [21]. Although MCPyV-LT expression
was not detected, the origin of some forms of LCS may
be MCPyV-infected LC. When confirmed, these findings
will open novel possibilities for therapeutic interventions
against LCS.
Methods
Patients and tissue samples of LCS
This study was approved by the Institutional Review
Board of Faculty of Medicine, Tottori University,
Yonago, Japan.
A total of seven tissues from patients with LCS were
analyzed. All tissues of LCS were obtained as formalin-
fixed paraffin-embedded (FFPE) samples.
Confirmation of accurate diagnosis of LCS
Diagnostic accuracy of all collected samples, histological
sections and immunohistochemistry for CD1a, S100 pro-
tein (S100), and CD207 (langerin) of all specimens was
confirmed by two pathologists on the basis of the diag-
nostic criteria [22].
DNA extraction from LCS tissues
DNA was extracted from each FFPE sample using the
QIAamp DNA FFPE Tissue Kit and Mini Kit (QIAGEN
GmbH, Hilden, Germany).
Multiplex quantitative PCR (Q-PCR) for MCPyV detection
Q-PCR was performed in a 10-μl reaction mix contain-
ing TaqMan® Copy number reference assay RNase P
(Applied Biosystems, Foster City, CA, USA) as internal
control [8]. A primer pair targeting the position 859–
934 (MCPyV-LT) on MCC350 (GenBank EU375803) was
[20] used. To determine the MCPyV-DNA ratio relative
to MCPyV-DNA of the reference MCC (MCC = 1.0) for
each case, Q-PCR was performed using an ABI PRISM
7900HT Sequence Detection System (Applied Biosys-
tems) as previously described [20]. The ratio of the virus
was determined using the viral signal in a positive MCC
sample as a reference (viral load = relative levels of
MCPyV, MCC = 1.0 copy/cell). Thresholds were plotted
against each standard sample. All reactions of samples
and controls were performed in triplicate, and the aver-
age was reported. The MCPyV-DNA ratio in each sam-
ple was determined on the basis of corresponding
standard curves.
Immunohistochemistry for detection of MCPyV-LT antigen
For detection of MCPyV-LT expression, immunohisto-
chemistry was performed using monoclonal antibody
CM2B4 (mouse monoclonal IgG2b, 200 μg/ml, sc-136172,
Santa Cruz Biotechnology, CA, USA) generated against a
peptide fragment of MCPyV-LT as immunogen [23,24].
MCC samples were used as controls throughout.
Statistical analysis
Comparisons of MCPyV viral load between MCPyV-
positive LCH and MCPyV-positive LCS were performed
using the Mann–Whitney U test. Differences between
values were considered statistically significant at P < 0.05.
Figure 2 Q-PCR data comparing MCPyV-positive LCH samples
and MCPyV-positive LCS samples. Q-PCR provides the viral load
of MCPyV (relative level of MCPyV (MCC = 1)) for MCPyV-positive LCH
samples and MCPyV-positive LCS samples plotted as box-whisker
plots (Mann–Whitney U test, P < 0.01). The median viral load data are
0.003 and 0.453 in MCPyV-positive LCH and MCPyV-positive LCS,
respectively. Abbreviations: LCH, Langerhans cell histiocytosis; LCS,
Langerhans cell sarcoma; MCC, Merkel cell carcinoma; MCPyV, Merkel
cell polyomavirus; Q-PCR, multiplex quantitative PCR.
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